Literature DB >> 9331928

Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and -2.

L S Stone1, C A Fairbanks, T M Laughlin, H O Nguyen, T M Bushy, M W Wessendorf, G L Wilcox.   

Abstract

Two highly-selective mu-opioid receptor agonists, endomorphin-1 and -2, were recently purified from bovine brain and are postulated to be endogenous mu-opioid receptor ligands. We sought to determine the effects of these ligands at the spinal level in mice. Endomorphin-1 and -2 produced short acting, naloxone-sensitive antinociception in the tail flick test and inhibited the behavior elicited by intrathecally injected substance P. Both endomorphin-1 and -2 were anti-allodynic in the dynorphin-induced allodynia model. Although acute tolerance against both endomorphins developed rapidly, endomorphin-1 required a longer pretreatment time before tolerance was observed. We conclude that the endomorphins are potent spinal antinociceptive and anti-allodynic agents and that they or related compounds may prove therapeutically useful as spinal analgesics.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331928     DOI: 10.1097/00001756-199709290-00025

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  20 in total

1.  Endomorphin analogues containing D-Pro2 discriminate different mu-opioid receptor mediated antinociception in mice.

Authors:  Shinobu Sakurada; Hiroyuki Watanabe; Takafumi Hayashi; Masayuki Yuhki; Tsutomu Fujimura; Kimie Murayama; Chikai Sakurada; Tsukasa Sakurada
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Effects of morphine and endomorphins on the polysynaptic reflex in the isolated rat spinal cord.

Authors:  Pao-Luh Tao; Yong-Shang Lai; Lok-Hi Chow; Eagle Yi-Kung Huang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-12-17       Impact factor: 3.000

3.  Effects of transgene-mediated endomorphin-2 in inflammatory pain.

Authors:  Shuanglin Hao; Darren Wolfe; Joseph C Glorioso; Marina Mata; David J Fink
Journal:  Eur J Pain       Date:  2008-06-24       Impact factor: 3.931

4.  A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic.

Authors:  S E Foran; D B Carr; A W Lipkowski; I Maszczynska; J E Marchand; A Misicka; M Beinborn; A S Kopin; R M Kream
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

5.  Effects of endomorphin-1 on open-field behavior and on the hypothalamic-pituitary-adrenal system.

Authors:  E Bujdosó; M Jászberényi; C Tömböly; G Tóth; G Telegdy
Journal:  Endocrine       Date:  2001-03       Impact factor: 3.633

6.  Effects of the endogenous opioid peptide, endomorphin 1, on supraoptic nucleus oxytocin and vasopressin neurones in vivo and in vitro.

Authors:  N Doi; C H Brown; H D Cohen; G Leng; J A Russell
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

7.  Naloxone blocks endomorphin-1 but not endomorphin-2 induced inhibition of tachykinergic contractions of guinea-pig isolated bronchus.

Authors:  A Fischer; B J Undem
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

8.  Nerve injury-induced changes in Homer/glutamate receptor signaling contribute to the development and maintenance of neuropathic pain.

Authors:  Ilona Obara; Scott P Goulding; Jia-Hua Hu; Matthias Klugmann; Paul F Worley; Karen K Szumlinski
Journal:  Pain       Date:  2013-04-02       Impact factor: 6.961

Review 9.  Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis.

Authors:  Carolyn A Fairbanks; Laura S Stone; George L Wilcox
Journal:  Pharmacol Ther       Date:  2009-04-23       Impact factor: 12.310

10.  The spinal antinociceptive effects of endomorphins in rats: behavioral and G protein functional studies.

Authors:  Hong Xie; James H Woods; John R Traynor; Mei-Chuan Ko
Journal:  Anesth Analg       Date:  2008-06       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.